A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Completed
Hoffmann-La Roche
Phase 1/Phase 2
2013-09-30
This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of
alectinib in participants with ALK-rearranged non-small cell lung cancer who failed
crizotinib treatment. In Phase I, cohorts of participants will receive escalating doses of
alectinib orally twice daily. In Phase II, patients who failed crizotinib treatment will
receive the recommended phase II dose.
A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment
Completed
Hoffmann-La Roche
Phase 1/Phase 2
2013-06-20
This open-label, non-randomized, multicenter, Phase 1/2 study will evaluate the safety and
efficacy of alectinib in participants with non-small cell lung cancer who have ALK mutation
and failed crizotinib treatment. In Part 1, cohorts of participants will receive escalating
doses of alectinib orally twice daily. In Part 2, participants will receive the recommended
phase 2 dose (RP2D) of alectinib as determined in Part 1. Treatment will continue in Part 1
and Part 2 on the same dose until disease progression. In Part 3, following disease
progression, participants without epidermal growth factor receptor (EGFR) mutation will be
offered continued treatment with alectinib, participants with EGFR mutations will be offered
a combination of alectinib and erlotinib.
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
Completed
Hoffmann-La Roche
Phase 1/Phase 2
2013-09-30
This non-randomized, open-label, multicenter study will evaluate the safety and efficacy of
alectinib in participants with ALK-rearranged non-small cell lung cancer who failed
crizotinib treatment. In Phase I, cohorts of participants will receive escalating doses of
alectinib orally twice daily. In Phase II, patients who failed crizotinib treatment will
receive the recommended phase II dose.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
